FindTrial
Sign In

The efficacy and safety of long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) in COPD patients with benign prostatic hyperplasia (BPH)

The efficacy and safety of long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) in COPD patients with benign prostatic hyperplasia (BPH) - The efficacy and safety of LAMA and LABA in COPD with BPH

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000009357
Enrollment
30
Registered
2012-11-19
Start date
2009-10-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD)

Interventions

long-acting muscarinic antagonist (LAMA) long-acting beta2-agonist (LABA)

Sponsors

Hamamatsu University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Patients with chronic obstructive pulmonary disease (COPD) Patients with benign prostatic hyperplasia (BPH) Patients can use the inhaled therapy Patients gave written informed consent

Exclusion criteria

Exclusion criteria: History of hyper-sensitivity to long-acting muscarinic antagonist (LAMA), long-acting beta2-agonist (LABA), inhaled corticosteroid (ICS) Patients with bronchial asthma Patients during acute exacerbation Presence of infectious disease, pneumothorax, and severe heart failure

Design outcomes

Primary

MeasureTime frame
Changes of lower urinary tract functions (IPSS, QOL index, maximum flow rate (Q-max) and average flow rate (Q-ave) in uroflowmetry, postvoid residual urine volume (PVR), bladder voiding efficiency (BVE))—

Secondary

MeasureTime frame
Changes of pulmonary functions (FEV1, FVC, inspiratory capacity (IC))—

Countries

Japan

Contacts

Public ContactHideki Yasui

Hamamatsu University School of Medicine Second Division, Department of Internal medicine

yassy19781119@yahoo.co.jp053-435-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026